An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
- Status
- COMPLETED
- Phase
- PHASE2
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE3
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
- Status
- COMPLETED
- Phase
- PHASE2
A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval
- Status
- COMPLETED
- Phase
- PHASE1
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
- Status
- COMPLETED
- Phase
- PHASE3
A Study in Subjects With Recurrent Malignant Glioma
- Status
- COMPLETED
- Phase
- PHASE2
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
- Status
- COMPLETED
- Phase
- PHASE2
Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Open Label Dose Escalation Study Of E7080
- Status
- COMPLETED
- Phase
- PHASE1